Epocrates, Inc. has announced Peter Brandt, a member of Epocrates’ board of directors, has been appointed as the company’s interim president and CEO. Brandt succeeds Rose Crane who stepped down from her position as president and CEO. The board has formed a search committee and initiated a search for a permanent replacement.
“Under Rose’s leadership, the company achieved an initial public offering, and she set the stage for future growth with the development and launch of innovative new
products,” said Patrick Jones, chairman of the Epocrates board of directors. “We thank Rose for her commitment and contributions and wish her well in her future endeavors.”
Peter Brandt, who joined the company’s board of directors in February 2011, has more than thirty years experience in the pharmaceutical industry. He most recently held the position of president and CEO of Noven Pharmaceuticals. He currently serves on the board of directors for Rexahn Pharmaceuticals, Auxilium Pharmaceuticals and the Population Council.
“Peter’s strong leadership and extensive knowledge of the healthcare industry will benefit the company during this transition,” said Jones. “We are fortunate that Peter is ready to step in and maintain positive momentum driving the company forward.”
“I’m excited about this opportunity and look forward to more closely supporting the company’s goals,” said Brandt. “I believe in the strength of the Epocrates business and have been consistently impressed with its talented and dedicated employees. As a company, we will remain focused on delivering innovative and valuable solutions for physicians to use at the point of care. Building on our recent development milestones, strategic realignments and strong financial position, we will take advantage of the many opportunities presented for future business growth.”